immunotherapy
Harnessing the power of the immune system
October 9, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Cancer Research UK, immunotherapy, pharma, pharmaceuticals
Dr Áine McCarthy, Senior Science Information Officer at Cancer Research UK, discusses the latest efforts to further understand the immunotherapies …
AstraZeneca’s Tagrisso secures Breakthrough Therapy Designation in first-line NSCLC
October 9, 2017Sales and Marketing AstraZeneca, Cancer, NSCLC, immunotherapy, lung cancer
AstraZeneca has announced that its targeted therapy, Tagrisso (osimertinib), has been awarded Breakthrough Therapy Designation by the FDA for the …
Roche’s Tecentriq scores approvals in metastatic lung and bladder cancer
September 27, 2017Research and Development, Sales and Marketing Cancer, EMA, EU, European Commission, Roche, bladder cancer, immunotherapy, lung cancer, pharma, tecentriq
It’s good news for Roche as the company’s immunotherapy drug Tecentriq secures approval from the European Commission to be used …
FDA locks down combo immunotherapy trials, Roche added to hold
September 19, 2017Manufacturing and Production, Sales and Marketing Roche, biotech, drugs, immunotherapy, pharma, pharmaceutical, tecentriq
The FDA has moved to ensure that all immunotherapy trials studying PD-1/L1 agents, alongside immunomodulatory medicines in certain blood cancers …
Lilly’s Cyramza combo boasts strong results in bladder cancer
September 11, 2017Research and Development, Sales and Marketing Eli Lilly, bladder cancer, cyramza, immunotherapy, pharma
Eli Lilly has announced new Phase 3 data at the European Society for Medical Oncology 2017 Congress which further add …
BMS hit by clinical trial hold from FDA
September 7, 2017Medical Communications, Sales and Marketing Bristol-Myers Squibb, biotech, drugs, immunotherapy, opdivo, pharma, pharmaceutical
The FDA has placed a partial hold on clinical trials involving Bristol-Myers Squibb’s immunotherapy treatment, Opdivo, when used in combination …
Immunotherapy firm develops breakthrough method for robust bispecific antibody production
August 30, 2017Research and Development antibodies, immunotherapy, merus, pharma, pharmaceuticals
A team of researchers at Dutch immunotherapy research firm Merus have developed an approach to efficiently manufacture bispecific antibodies which …
Independent research may change the immunotherapy game
August 17, 2017Research and Development Cancer, biotech, drugs, immunotherapy, pharma, pharmaceutical
Immunotherapy treatments that focus on the PD-L1 protein have become some of the most exciting to emerge in cancer treatment. …
Takeda strikes partnership to develop single-drug cancer combo immunotherapies
August 14, 2017Medical Communications, Research and Development, Sales and Marketing Cancer, Takeda, immunotherapy, medicine, pharma, pharmaceuticals
Japanese pharma giant Takeda has announced that it is to partner up with US-based Shattuck Labs in a collaboration to …
Ending the era of $100,000 cancer drugs
August 11, 2017Medical Communications, Research and Development Cancer, biotech, drugs, healthcare, immunotherapy, life sciences, medicine, pharma, pharmaceutical
Paul Workman, Chief Executive and President of the Institute of Cancer Research, examines the spiralling cost of cancer treatments and …
Cancer Research UK partners with Biotecnol to deliver experimental solid tumour drug
August 10, 2017Research and Development, Sales and Marketing Biotecnol, Cancer, Cancer Research UK, drugs, immunotherapy, life sciences, medicine, pharma, pharmaceutical
Cancer Research UK (CRUK) has announced a collaboration with Biotecnol, an immuno-oncology firm focused on the development of multifunctional antibodies …
AZ attempts to clear dust of Mystic trial with $8.5 billion MSD deal
July 27, 2017Medical Communications, Sales and Marketing AstraZeneca, MSD, Merck, biotech, drugs, immunotherapy, mystic, pharma, pharmaceutical
It will be some time before the Mystic catastrophe hoo-ha dies down for AstraZeneca but it made a pre-emptive move …
Celgene plays catch up with $1.4 billion immunotherapy deal
July 7, 2017Medical Communications, Sales and Marketing BeiGene, Celgene, immunotherapy, pd-1
Those commentating on Celgene’s latest deal seem to be equally divided between two camps: it is too much money, too …
FDA shutters MSD’s Keytruda combination trials in myeloma
July 6, 2017Medical Communications, Research and Development MSD, immunotherapy, keytruda, pd-1
Following on from the news last month that enrolment for Keytruda being used alongside Celgene’s Imnovid and Revlimid would have …
American Cancer Society and Melanoma Research Alliance join forces to bring down immunotherapy side-effects
June 29, 2017Medical Communications, Research and Development American Cancer Society, Cancer, Melanoma Research Alliance, immunotherapy
The American Cancer Society (ACS) and the Melanoma Research Alliance (MRA) have formed a research partnership to reduce the impact …
Latest content
Five Facts about cardiovascular disease
Artificial hearts: a century of innovation
